Results 71 to 80 of about 57,323 (255)

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori, Tateaki Naito, Nobuko Konishi, Tetsuya Tsuji, Ikumi Takashima, Ryotaro Ide, Masakazu Fujiwara, Atsuki Yamamoto, Yusuke Takagi, Mizue Ogi, Shinya Uematsu, Hiroshi Kitagawa, Koichi Takayama   +12 more
wiley   +1 more source

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system

Scientific Reports, 2020
We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model ...
Nathan McDannold, Yongzhi Zhang, Jeffrey G. Supko, Chanikarn Power, Tao Sun, Natalia Vykhodtseva, Alexandra J. Golby, David A. Reardon   +7 more
doaj   +1 more source

The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. [PDF]

PLoS ONE, 2015
Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens. Mucositis causes cell damage, bacterial/endotoxin translocation and production of cytokines including IL-1 and IL-18.
Deysi V T Wong, Roberto C P Lima-Júnior, Cibele B M Carvalho, Vanessa F Borges, Carlos W S Wanderley, Amanda X C Bem, Caio A V G Leite, Maraiza A Teixeira, Gabriela L P Batista, Rangel L Silva, Thiago M Cunha, Gerly A C Brito, Paulo R C Almeida, Fernando Q Cunha, Ronaldo A Ribeiro   +14 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Irinotecan-induced colitis

, 2005
Irinotecan (CPT-11) is a chemotherapeutic drug used to treat tumors by acting on malignant cells through inhibition of DNA topoisomerase I and inducing premature apoptosis.
Bouzourene, H., Chaubert, P., Sandmeier, D.   +2 more
core   +1 more source

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

BMC Cancer
Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha   +20 more
doaj   +1 more source

P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil

ADMET and DMPK, 2015
We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg, Manu Jaggi, Roop K. Khar, Sushama Talegaonkar   +3 more
doaj   +1 more source

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

Frontiers in Pharmacology, 2020
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera, Pau Riera, Pau Riera, Alícia Artigas-Baleri, Juliana Salazar, Ana Sebio, Anna C. Virgili, María Jesús Arranz, David Páez, David Páez   +9 more
doaj   +1 more source

The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis [PDF]

, 2015
OBJECTIVE The treatment of lupus nephritis is still an unmet medical need requiring new therapeutic approaches. Our group found recently that irinotecan, an inhibitor of topoisomerase I (topo I), reversed proteinuria and prolonged survival in mice ...
Keil, Andreas, Schmid, Ralph, Frese, Steffen R., Andreas Keil, Frese-Schaper, Manuela, Steffen Frese, Ralph A. Schmid, Steiner, Selina, Meike Körner, Manuela Frese‐Schaper, Körner, Meike, Selina K. Steiner   +11 more
core   +1 more source